Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (noted as Skye Bioscience, Inc. in request metadata) on October 26, 2016. The report details a private placement financing transaction and the entry into material definitive agreements with officers and directors.
Key Financial Metrics and Transaction Details
- Capital Raised: $500,000 aggregate purchase price.
- Securities Issued: 500 shares of Series C Convertible Preferred Stock.
- Price Per Share: $1,000 per Preferred Share.
- Conversion Terms: Convertible into common stock at a price of $0.40 per share.
- Investor Type: Accredited investors under Regulation D.
- Liquidity/Debt: The filing does not provide specific data on total company debt, cash flow, or liquidity ratios outside of this transaction.
Material Changes and Agreements
The Company entered into Lock-Up Agreements with all officers and directors, restricting the sale of their common stock for 90 days following the earlier of the effectiveness of a registration statement for the new shares or eligibility for sale under Rule 144. Additionally, a Registration Rights Agreement was executed, requiring the Company to file a registration statement within 30 days of closing. Failure to do so within specified timeframes triggers a penalty of 2.0% of the aggregate purchase price per month.
Outlook, Risks, and Unusual Items
- Anti-Dilution and MFN: The Series C stock includes anti-dilution protection and a "most favored nation" provision, allowing investors to exchange shares for new securities issued in subsequent financings on identical terms.
- Conversion Limitations: Conversion is limited to prevent any holder from acquiring beneficial ownership of more than 4.99% of outstanding common stock (increasable to 9.99% in certain circumstances).
- Regulatory Compliance: The offering relied on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, involving no general solicitation.
Investor Verification Checklist
- Verify the effectiveness date of the registration statement for the resale of the Series C Preferred Stock to assess potential penalty payments.
- Confirm the exact number of outstanding common shares to calculate the dilution impact of the $0.40 conversion price.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific anti-dilution formulas and fundamental transaction rights.
- Check subsequent filings to ensure the 30-day registration filing deadline was met.